度洛西汀和舍曲林治疗抑郁症的对照研究

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (2): 207-209.

度洛西汀和舍曲林治疗抑郁症的对照研究

沈鑫华, 钱敏才, 林敏, 费小聪, 王士良

浙江省湖州三院神经症与心身疾病科, 湖州313000, 浙江

收稿日期:2008-09-02 修回日期:2009-02-10 出版日期:2009-02-26 发布日期:2020-10-30
作者简介:沈鑫华, 男, 硕士, 主任医师, 研究方向:焦虑抑郁障碍的基础与临床。Tel:13757289039 　E-mail:shenxinhuasun@sina.com

A control study of duloxetine and sertraline in the treatment of patients with depression

SHEN Xin-hua, QIAN Min-cai, LIN Min, FEI Xiao-cong, WAN Shi-liang

Department of Neurosis and Psychosomatic Diseases, Huzhou 3rd Hospital, Huzhou 313000, Zhejiang, China

Received:2008-09-02 Revised:2009-02-10 Online:2009-02-26 Published:2020-10-30

摘要/Abstract

摘要： 目的:观察度洛西汀治疗抑郁症的疗效和安全性。方法:98 例符合CCMD-3 抑郁发作诊断标准的患者随机分为度洛西汀组(60 mg/d, n =48) 和舍曲林组(50 ～ 150 mg/d, n =50), 疗效采用汉密尔顿抑郁量表(HAMD) 17 项评分, 不良反应采用治疗时出现的症状量表(TESS) 和实验室检查来评定。疗程均为6 周。结果:度洛西汀组痊愈率39.6 %, 有效率68.8 %;舍曲林组痊愈率30.0 %, 有效率58.0 %, 两组比较差异无统计学意义。但度洛西汀组在HAMD 量表减分值方面,第1 、2 、4 周均更明显。度洛西汀最常见的不良反应为食欲减退或厌食、口干、出汗、便秘、恶心呕吐。两组脱落率分别为6.3 %及8.0 %, 无统计学差异。结论:度洛西汀治疗抑郁症疗效好, 不良反应少。

关键词: 度洛西汀, 舍曲林, 安全性, 疗效/耐受性, 抑郁症

Abstract: AIM: To study the efficacy and safety of duloxetine in the treatment of patients with depression.METHODS: In this 6-week randomized control trial, patients meeting CCMD-3 criteria for depressive episode were randomizedly divided to duloxetine group (60 mg/d, n =48) and sertraline group (50 -150 mg/d, n =50).Clinic effectiveness was evaluated using HAMD, adverse reactions and safety were assessed with TESS and laboratory examination.RESULTS: The remission rate and response rate were 39.6 % and 68.8 % for duloxetine group and 30.0 % and 58.0 % for sertraline group respectively, without statistically significant difference between two groups.But duloxetine- treated patients showed significantly greater improvement in the HAMD total score at week 1, 2, 4 respectively.The main adverse reactions were lack of appetite, dry mouth, sweating, constipation, nausea and vomit.The dropped out rates were 6.3 % for duloxetine group and 8.0 % for sertraline group respectively, without statistically significant difference between two groups.CONCLUSION: Duloxetine appeared to be a safe and effective treatment for depression.

Key words: duloxetine, sertraline, safety, efficacy/tolerability, depression

中图分类号:

R749.4

沈鑫华, 钱敏才, 林敏, 费小聪, 王士良. 度洛西汀和舍曲林治疗抑郁症的对照研究[J]. 中国临床药理学与治疗学, 2009, 14(2): 207-209.

SHEN Xin-hua, QIAN Min-cai, LIN Min, FEI Xiao-cong, WAN Shi-liang. A control study of duloxetine and sertraline in the treatment of patients with depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 207-209.

参考文献

[1] Kessler RC, ChiuWT, Demler O, et al.Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication[J].Arch Gen Psychiatry, 2005, 62(6):617-627.
[2] Rush AJ, Fava M, Wisniewski SR, et al.Sequenced treatment alternatives to relieve depression (STAR＊D): rationale and design[J].Control Clin Trials, 2004, 25 (1):119-142.
[3] Detke MJ, Lu Y, Goldstein DJ, et al.Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression[J].J Psychiatr Res, 2002, 36(6):383-390.
[4] Detke MJ, Lu Y, Goldstein DJ, et al.Duloxetine, 60 mg once daily, for major depressive disorder:a randomized double-blind placebo-controlled trial[J].J Clin Psychiatry, 2002, 63(4):308-315.
[5] Goldstein DJ, Mallinckrodt C, Lu Y, et al.Duloxetine in the treatment of major depressive disorder:a double-blind clinical trial[J].J Clin Psychiatry, 2002, 63(3):225-231.
[6] Lee P, Shu L, Xu X, et al.Once-daily duloxetine 60 mg in the treatment of major depressive disorder:multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil[J]. Psychiatry Clin Neurosci, 2007, 61(3):295-307.
[7] Perahib DG, Pritchett YL, Kajdasz DK, et al.A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder[J].J Psychiatr Res, 2008, 42(1):22-34.
[8] Mallinckrodt CH, Parkash A, Houston JP, et al.Differential antidepressant symptom efficacy:placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram) [J].Neuropsychobioiogy, 2007, 56(2/3):73-85.
[9] Klan A, Bose A, Alexopoulos GS, et al.Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder[J].Clin Drug Investig, 2007, 27(7):481-492.
[10] Perahia DG, Kajdase DK, Walker DJ, et al.Duloxetine 60 mg once daily in the treatment of milder major depressive disorder[J].Int J Clin Pract, 2006, 60(5):613-620.
[11] Perahia DG,Wang F, Mallinckrodt CH, et al.Duloxetine in the treatment of major depressive disorder:a placeboand paroxetine-controlled trial[J].Eur Psychiatry, 2006, 21(6):367-378.
[12] Hudson JI, Perahia DG, Gilaberte I, et al.Duloxetine in the treatment of major depressive disorder:an open-lable study[J].BMC Psychiatry, 2007, 7:43.

[1]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[2]	刘敏, 孔祥, 章叶, 顾逸飞, 项雪梅, 黄凯. 经口吸入制剂在中国健康受试者生物等效性试验中的安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(10): 1131-1138.
[3]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[4]	何滕, 许向阳, 徐祥清, 刘存明, 杨春. 氯胺酮治疗抑郁症的过去、现在及未来[J]. 中国临床药理学与治疗学, 2022, 27(10): 1125-1132.
[5]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[6]	王叶情, 王宇红, 刘检, 赵洪庆, 邹蔓姝. 胆囊收缩素与抑郁症的相关性研究进展[J]. 中国临床药理学与治疗学, 2021, 26(6): 672-679.
[7]	陈颖, 袁勇贵. 中药单体、药对、复方、中成药治疗抑郁症研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 586-593.
[8]	金晶, 程虹. 线粒体能量代谢参与抑郁症发病的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1193-1199.
[9]	杨世涛, 祝一虹, 唐文新. 阿立哌唑联合度洛西汀对难治性抑郁的疗效及对血管内皮生长因子的作用研究[J]. 中国临床药理学与治疗学, 2020, 25(8): 937-942.
[10]	葛薇，盛文燕，许琦彬，李秋实，苏铃雅，吴双庆. 选择性5-羟色胺再摄取抑制剂类抗抑郁药舍曲林对产后抑郁患者眼表功能影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 440-446.
[11]	冯睿，张佳莉，赫明超，李钺，张岩. 中药及其活性成分防治抑郁症的药理靶点与临床应用[J]. 中国临床药理学与治疗学, 2020, 25(4): 467-474.
[12]	潘露萍，石武杰，沈志鹏. 依托泊苷联合卡铂用于复发性髓母细胞瘤患儿的疗效与安全性[J]. 中国临床药理学与治疗学, 2020, 25(2): 189-195.
[13]	石莉莉, 刘兴安, 单国用. 阿帕替尼后线治疗标准方案失败的晚期结直肠癌的疗效和安全性及疗效预测因子的初步分析[J]. 中国临床药理学与治疗学, 2020, 25(12): 1388-1394.
[14]	杨海静，郁继诚，王晶晶，李南洋，吴菊芳，张海，薛涛，戴卫国，丁天凌，曹国英. 生物制剂I期临床试验中的风险管控：案例分享[J]. 中国临床药理学与治疗学, 2020, 25(1): 44-48.
[15]	王思捷，张峻，李骞，黄桦，王晶晶，周琼，姚勤. 艾司西酞普兰用于妊娠期抑郁的安全性研究探讨[J]. 中国临床药理学与治疗学, 2019, 24(9): 1070-1074.